Nodality develops next‑generation personalized medicine diagnostic tests focused on cancer and autoimmune disease. Its immediate commercial plan centers on launching a first test for acute myelogenous leukemia. The company also plans to advance research and development programs across other hematologic malignancies, autoimmune diseases, and solid tumors. Nodality completed a $15.5M venture capital financing to support these commercial and R&D activities. The financing is intended to fund both the launch and ongoing/new research programs. The article does not disclose operating metrics.

Total raised

$16M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2010